University of Angers, MINT Inserm 1066 CNRS 6021, Angers, France; CHU Angers, 4 Rue Larrey, 49033 Angers, France.
University of Angers, MINT Inserm 1066 CNRS 6021, Angers, France.
Drug Discov Today. 2021 Oct;26(10):2259-2268. doi: 10.1016/j.drudis.2021.04.017. Epub 2021 Apr 20.
Nanomedicines have been developed for more than four decades to optimize the pharmacokinetics (PK) of drugs, especially absorption, distribution, and stability in vivo. Unfortunately, only a few drug products have reached the market. One reason among others is the lack of proper PK modeling and evaluation, which impedes the optimization of these promising drug delivery systems. In this review, we discuss the specificity of nanomedicines and propose key parameters to take into account for future accurate PK evaluation of nanomedicine. We believe that this could help these innovative drug products to reach to market and change the fate of many diseases.
纳米药物已经发展了四十多年，旨在优化药物的药代动力学（PK），特别是体内的吸收、分布和稳定性。不幸的是，只有少数药物产品进入了市场。其中一个原因是缺乏适当的 PK 建模和评估，这阻碍了这些有前途的药物输送系统的优化。在这篇综述中，我们讨论了纳米药物的特异性，并提出了未来准确评估纳米药物 PK 时需要考虑的关键参数。我们相信，这将有助于这些创新药物产品进入市场，并改变许多疾病的命运。
